Drug Profile
IONIS GCCRRx
Alternative Names: IONIS-GCCRRx; ISIS-426115; ISIS-GCCR-RX; ISIS-GCCRRxLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Ionis Pharmaceuticals
- Class Antihyperglycaemics; Antisense oligonucleotides
- Mechanism of Action Glucocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Type 2 diabetes mellitus
- No development reported Cushing syndrome
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cushing's syndrome(In volunteers) in USA (SC)
- 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
- 01 May 2015 ISIS Pharmaceuticals completes a phase-II clinical trial in Type-2 diabetes mellitus (Adjunctive treatment) in Canada, Romania and South Africa (SC) (NCT01968265)